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Fig 1. A, Syringocystadenoma papilliferum (arrow) developing over hyperkeratosis of the
right nipple. B, Nevoid hyperkeratosis of the nipple. Orthokeratotic hyperkeratosis, acanthosis,
papillomatosis, and a sparse superficial perivascular lymphocytic infiltrate (Hematoxylin-eosin
stain; original magnification:340). C andD, Syringocystadenoma papilliferum. Papillary foci in
continuity with the surface squamous epithelium. These papilla had a bilayered epithelium of
inner columnar cells showing decapitation secretion and outer flattened cells as well as a
fibrovascular core containing abundant plasma cells. C and D, Hematoxylin-eosin stain;
original magnifications: C, 340; D 3200.
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patient with high-risk melanoma
To the Editor: Ipilimumab is a biologic anticancer
therapy used in the treatment of advanced
melanoma. Ipilimumab’s antitumor effect stems
from CTLA-4 blockade, which results in the non-
specific activation of T cells. Rash is a common side
Open access under CC BY-NC-ND license.effect of ipilimumab, with all-grade rash occurring in
approximately 25% of patients and high-grade rash
in 2.4%.1 Cases of toxic epidermal necrolysis,
Stevens-Johnson syndrome, and DRESS have been
reported after ipilimumab exposure.2,3
We present what, to our knowledge, is the first
reported case of Sweet syndrome associated with
ipilimumab therapy. The patient was a 70-year-old
white woman with a history of stage IIIB nodular
melanoma. Six months before admission, she un-
derwent wide local excision and lymphadenectomy
with no evidence of residual disease. Because of her
high risk for recurrence, she elected to enroll in a
clinical trial for adjuvant chemotherapy and was
randomized to receive infusions of high-dose
ipilimumab (10 mg/kg) every 3 weeks. Nineteen
days after receiving her fourth ipilimumab infusion,
she presented to the hospital with a painful rash
(Fig 1) and fever, with temperature of 38.48C.
Cutaneous examination revealed multiple erythem-
atous and tender papules and nodules on her face
and upper extremities, as well as pseudovesicular
lesions on the lips and oral mucosa. Multiple skin
biopsies showed similar histopathologic features of a
Fig 1. Erythematous, tender papules and nodules with
hemorrhagic crusting on the face and lips, consistent with
a clinical diagnosis of Sweet syndrome.
Fig 2. Skin biopsy from the arm with a dense dermal
neutrophilic infiltrate with cellular debris. Hematoxylin-
eosin stain; original magnifications: 32; inset, 320.
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debris but no fibrinoid changes of vasculitis (Fig 2).
Special stains were negative for microorganisms
( fungal, bacterial, acid-fast). The clinical and
histopathologic findings were consistent with a
diagnosis of Sweet syndrome. She was treated with
high-dose intravenous corticosteroids (1.8 mg/kg
prednisone equivalent) and dapsone with dramatic
clinical improvement. A slow taper of corticosteroids
was initiated after 2 weeks of treatment with no
resulting rebound.
This case appears to meet criteria for drug-
induced Sweet syndrome (DISS), given the
abrupt onset of a typical rash, associated fever,
features of neutrophilic dermatosis on histo-
pathology, an appropriate temporal relationship
with the suspected drug, and the dramatic
resolution after systemic corticosteroid therapy.
To our knowledge, ipilimumab-induced Sweet syn-
drome has not been previously reported in
the medical literature.1-3 The development of DISS
in a patient receiving immunostimulatory therapy
is particularly interesting given the relative paucityof knowledge regarding the pathophysiologic mech-
anism underlying Sweet syndrome. Historically,
Sweet syndrome has been thought of as a hypersen-
sitivity reaction; however, cytokine dysregulation
has also been implicated.4 Given the relative
novelty of ipilimumab use, it remains to be
seen whether CTLA-4 blockade results in an
increased risk for DISS over other immune stimula-
tory therapies.
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Vancomycin-associated neutrophilic dermatitis
histologically mimicking Cryptococcus
To the Editor:Morphologic mimic of Cryptococcus in
a neutrophilic dermatitis (MMCND) is a recently
described entity that is virtually indistinguishable
from cutaneous cryptococcal infection when routine
histopathology is used.
Case: A 63-year-old man with recurrent
Cryptococcus difficile colitis was treated with oral
vancomycin; 24 hours later, an eruption on his back
with ‘‘burning’’ symptoms developed. This eruption
spread to involve his arms and thighs. The next
day, 2 tense bullae appeared on his abdomen. The
